Cervical cancer control includes primary prevention through vaccination to prevent human
papillomavirus (HPV) infection and secondary prevention through screening to detect and …

Since being introduced in the 1940s, cervical cytology–despite its limitations–has had
unequivocal success in reducing cervical cancer burden in many countries. However, we …

Over the past 25 years, not only have “high-risk” human papillomaviruses (HPVs) been
identified as the causal agents of cervical cancer, but also accurate clinical assays have …

Several randomized trials have demonstrated that HPV-based cervical cancer screening is
more effective than cytology-based screening. A pooled analysis of long-term follow-up data …

Human Papillomavirus (HPV) vaccines will likely have an impact as a preventive strategy for
cervical cancer. Screening for precancerous lesions cannot be discontinued because …

Worldwide, there are several approaches for the prevention of cervical cancer, and in the
near future it is likely that human papillomavirus (HPV) vaccination and HPV-based …

With the introduction of cervical screening programs, the incidence and mortality of cervical
cancer has been drastically reduced. Techniques such as the traditional Papanicolaou test …

Human papillomavirus (HPV) vaccination is expected to reduce the burden of cervical
cancer in most settings; however, it is also expected to interfere with the effectiveness of …

Since the early 1950s, Papanicolaou (“Pap”) cytology screening has dramatically reduced
cervical cancer mortality in most high-income settings. Currently, human papillomavirus …

We used modeling approaches to estimate the impact of human papillomavirus (HPV)
vaccination on the performance of Pap cytology screening under different assumptions of …